Bicycle finally falls
The company admits defeat with zelenectide.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
Rusfertide still needs to be Verified
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
FDA red and green lights: February 2026
The month saw the first commissioner's priority voucher approval in oncology.
